Lipoprotein(a) testing
Lipoprotein(a) testing has been studied in 5 papers since 2026: 4 observational studies in people, 1 review; 5 in the past year. The newest paper, Nov 2, 2026: “Impact of Lipoprotein(a) Testing on Lipid-Lowering Therapy Use and LDL-C Goal Attainment in Patients with Atherosclerotic Cardiovascular Disease: A Difference-in-Differences Analysis”.
5 papers study it6 findingsUpdated
2 new papers in 30 daysSee all 5 papers on lipoprotein(a) testing
At a glance
The findings reach people, from one lab or study. 3 independent labs in 1 country.
“Lp(a) testing was associated with greater LLTI (odds ratio [OR], 2.11 [95% CI, 1.95-2.29])”
None of its findings points the other way.
- 3 independent labs in 1 country
- 5 of 6 findings with company ties
- Humans4
What is lipoprotein(a) testing linked with?
6Studies link lipoprotein(a) testing with 6 measures, among them LDL cholesterol, lipid-lowering therapy adherence and lipid-lowering therapy use.
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Lipoprotein(a) testing is associated with LDL cholesterol in humans (−4.43 mg/dL (95% CI, −5.51 to −3.35 mg/dL)).
“those receiving Lp(a) testing experienced greater reductions in LDL-C (–4.43 mg/dL [95% CI, –5.51 to –3.35 mg/dL])”
HumansPatients with atherosclerotic cardiovascular disease and available LDL-C measurements; matched difference-in-differences comparison12 months before and after testing
AHA Scientific Sessions 2026 abstract
Lipid-lowering therapy adherence
upin humans1
1 study
Lipid-lowering therapy adherence
upin humans1
Lipoprotein(a) testing is associated with lipid-lowering therapy adherence in humans (6.51% greater improvement (95% CI, 5.45%-7.57%); P<0.001).
“as well as greater improvement in LLT adherence (6.51% [95% CI, 5.45%-7.57%]) with all P-values <0.001.”
HumansPatients with atherosclerotic cardiovascular disease; adherence defined as proportion of days covered ≥80%12 months before and after testingBoth; 45% femalesn = 32,466
AHA Scientific Sessions 2026 abstract
Lipid-lowering therapy use
upin humans1
1 study
Lipid-lowering therapy use
upin humans1
Lipoprotein(a) testing is associated with lipid-lowering therapy use in humans (6.56% greater increase (95% CI, 5.83%-7.29%); P<0.001).
“Lp(a) testing was associated with greater increases in LLT use compared with the matched control group (6.56% [95% CI, 5.83%-7.29%])”
HumansPatients with atherosclerotic cardiovascular disease; matched difference-in-differences comparison12 months before and after testingBoth; 45% femalesn = 32,466
AHA Scientific Sessions 2026 abstract
High or very high lipoprotein
upin humans1
1 study
High or very high lipoprotein
upin humans1
Lipoprotein(a) testing is associated with high or very high lipoprotein in humans Among recorded lipoprotein(a) values at Bay Area Community Health (17% had high or very high Lp(a) (≥107 nmol/L)).
“Of 2,431 recorded values, 17% identified patients with high or very high Lp(a) (≥107 nmol/L).”
HumansAmong recorded lipoprotein(a) values at Bay Area Community HealthJune 2024 to April 2026n = 2,431
AHA Scientific Sessions 2026 abstract
LDL-C goal attainment
upin humans1OR 1.22
1 study
LDL-C goal attainment
upin humans1OR 1.22
Lipoprotein(a) testing is associated with LDL-C goal attainment in humans (OR 1.22, 95% CI 1.12-1.33).
“Lp(a) testing was associated with greater LLTI (odds ratio [OR], 2.11 [95% CI, 1.95-2.29]), LDL-C testing (OR, 1.27 [95% CI, 1.19-1.36]), and LDL-C goal attainment (OR, 1.22 [95% CI, 1.12-1.33]).”
Humans12 months
Journal of the American Heart Association
Lipid-lowering therapy intensification
upin humans1OR 2.11
1 study
Lipid-lowering therapy intensification
upin humans1OR 2.11
Lipoprotein(a) testing is associated with lipid-lowering therapy intensification in humans (OR 2.11, 95% CI 1.95-2.29).
“Lp(a) testing was associated with greater LLTI (odds ratio [OR], 2.11 [95% CI, 1.95-2.29])”
Humans12 months
Journal of the American Heart Association